Chlorpromazine-induced severe skin pigmentation and corneal opacities in a patient with schizophrenia.
Department of Dermatology, Fundación Jiménez Díaz, Madrid, Spain.
Ana María
AM
Molina-Ruiz
Department of Dermatology, Hospital Virgen del Rocío, Sevilla, Spain.
Águeda
Á
Pulpillo
Department of Psychiatry, Hospital Madrid Puerta del Sur, Madrid, Spain.
Rosa María
RM
Molina-Ruiz
Department of Ophthalmology, Hospital Virgen del Rocío, Sevilla, Spain.
Teresa
T
Sagrario
Department of Dermatology, Fundación Jiménez Díaz, Madrid, Spain.
Luis
L
Requena
D001707:Biopsy, Needle; D002746:Chlorpromazine / Q000009:adverse effects* / Q000627:therapeutic use; D003318:Corneal Opacity / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced* / Q000473:pathology; D007150:Immunohistochemistry; D008134:Long-Term Care; D008875:Middle Aged; D018570:Risk Assessment; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012720:Severity of Illness Index; D013472:Sunlight / Q000009:adverse effects*
D002746:Chlorpromazine